Solve Annual Meeting May 6th & 7th 2025

Auspiciado por nuestro presidente de honor, el Excmo. Sr. D. Mariano Esteban Rodríguez, se ha celebrado en la RANF el congreso SOLVE (the project has received funding from the European Union’s Horizon Research and Innovation program under Grant Agreement No. 101137185).

Tuesday, May 6, 2025 starts with the welcome remarks and project overview with Yves Levy (Inserm-VRI) & Mariano Esteban (CSIC). Session 1 was about “Design and immunogenicity of the new generation of vaccines (WP1 & WP2)” moderated by Giuseppe Pantaleo; “MVA vaccine platform”, Mariano Esteban (CSIC); “DC targeting vaccine platform”, Mireille Centlivre (Inserm-VRI); “Nanoparticles vaccine platform”, Laurent Pérez (CHUV); “mRNA vaccine platform”, Youlia Serikova (Quantoom); and “Immunogenicity in preclinical model” with Véronique Godot (Inserm-VRI) and Mariano Esteban (CSIC).
Session 2: “Evaluation of vaccine immune responses (WP4, WP5 & WP6)” moderated by Yves Levy; “Innate immunity” with Craig Fenwick (CHUV). “Humoral and B cell responses (including B cell repertoire)”, Aurélien Sokal (UPEC)& Craig Fenwick (CHUV) and finally “Cellular and T cell responses with Aurelie Wiedemann (Inserm-VRI)”, Yannick Muller (CHUV).

Wednesday, March 7, 2024, starts with session 3: “Clinical trial and perspective for pandemic preparedness (WP3 & WP8)” moderated by Rodolphe Thiebaut; “Experimental Medicine Trial”
with Giuseppe Pantaleo (CHUV) & Linda Wittkop (Inserm-MART); “Stakeholder perspectives on approaches to increase pandemic preparedness”, Alessandra Blonda (KUL).
Session 4: “Data integration and modeling / Access to clinical and immunological data (WP7)” Moderator: Jean-Daniel Lelievre; “Data Science” by Rodolphe Thiebaut (Inserm-SISTM)
Session 5: “Coordination, management and outcomes dissemination (WP9)”, coordination management and outcomes dissemination Catherine Clusel (Inserm-Transfert), Nicolas Bernaud (Inserm-VRI); “SAB Breakout: Internal discussion of SAB members”; Scientific Advisor Board remarks/feedback, Sarah Walker (University College London), Florian Klein (University of Cologne) & James Tartaglia (Independent Consultant—formerly Sanofi Vaccines); Closing remarks, Yves Levy (Inserm-VRI).